# South America Personalized Medicine Market > South America Personalized Medicine Market Research Report By Product Outlook (Personalized Medicine Diagnostics, Personalized Medicine Therapeutics, Personalized Medical Care, Personalized Nutrition and Wellness), By Application Outlook (Oncology, CNS, Immunology, Respiratory, Others), and By End-User Outlook (Hospitals, Diagnostic Centers, Research Academic Institutes, Others) -Forecast to 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 5.9% - **2024:** $ 59.67 Billion - **2025:** $ 63.19 Billion - **2035:** $ 112.14 Billion - **Key Players:** Roche (CH), Thermo Fisher Scientific (US), Illumina (US), Novartis (CH), GSK (GB), Pfizer (US), AbbVie (US), Bristol-Myers Squibb (US), Amgen (US) **Report ID:** MRFR/HC/43635-HCR · **Pages:** 200 · **Author:** Satyendra Maurya & Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/south-america-personalized-medicine-market-45315 --- ## Market Summary ## **South America Personalized Medicine Market Overview** As per MRFR analysis, the South America Personalized Medicine Market Size was estimated at 38.96 (USD Billion) in 2023. The South America Personalized Medicine Market is expected to grow from 41.77 (USD Billion) in 2024 to 85.91 (USD Billion) by 2035. The South America Personalized Medicine Market CAGR (growth rate) is expected to be around 6.775% during the forecast period (2025-2035). ## **Key South America Personalized Medicine Market Trends Highlighted** The market for personalized medicine is expanding significantly in South America due to a number of causes. The rising incidence of chronic illnesses like diabetes and cancer, which creates a need for specialized treatment methods, is one of the major factors propelling the market. Additionally, developments in genetic and biotechnology research are essential because they allow medical professionals to create tailored treatments that enhance patient outcomes. This tendency is being further supported by the South American governments, who are actively sponsoring health initiatives targeted at improving individualized healthcare services. The potential for cooperation between regional healthcare providers and global biotech companies is one of the opportunities in the South American customized medicine sector. South American nations may improve their healthcare systems and provide individualized therapies that address particular patient needs by utilizing cutting-edge technologies and research. Furthermore, people are more inclined to look for individualized medical choices as a result of increased health consciousness, which creates more opportunities for market growth. Artificial intelligence and data analytics have been increasingly used into South American personalized health procedures in recent years. Better patient monitoring and treatment planning are made possible by this technological integration. Researchers and medical professionals are also being prompted to investigate genetic profiles and biomarkers, which are crucial for creating successful tailored medicines, as a result of government sectors' growing emphasis on precision medicine efforts. All of these factors point to a strong shift in South America toward more individualized healthcare, which is encouraging for the region's personalized medicine market. ## Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **South America Personalized Medicine Market Drivers** ### **Increasing Incidence of Chronic Diseases** The rise in chronic diseases such as cancer, diabetes, and heart disease is a significant driver of the South America Personalized Medicine Market. For instance, the World Health Organization (WHO) has reported a 17% increase in cancer cases in South America over the past decade, highlighting a pressing need for personalized treatment options that cater to individual genetic profiles. As countries like Brazil and Argentina continue to modernize their healthcare systems, organizations such as the Brazilian National Cancer Institute (INCA) are focusing on the implementation of tailored therapies which can result in improved patient outcomes. This trend not only indicates a growing patient population but also fosters innovation and investment in personalized medicine approaches across the region, further enhancing the market growth potential. ### **Technological Advancements in Genomics and Bioinformatics** Rapid advancements in genomic technologies and bioinformatics are playing a crucial role in shaping the South America Personalized Medicine Market. With the decreasing cost of genomic sequencing, which has dropped by more than 99% in the past decade, healthcare organizations and research institutions in South America are increasingly able to implement personalized medicine approaches. For example, the Brazilian Institute of Geography and Statistics (IBGE) has initiated various projects promoting bioinformatics capabilities among local universities, fostering a skilled workforce in cutting-edge technologies. Improved access to such technology allows for more precise diagnostics and treatments tailored to the genetic makeup of individuals, thereby enhancing the efficacy and efficiency of healthcare delivery in the region. ### **Government Support and Regulation for Personalized Medicine** Government initiatives and regulatory support are influential factors driving the growth of the South America Personalized Medicine Market. Several South American countries have introduced policies aimed at promoting innovation in healthcare, particularly in the field of personalized medicine. The Argentine government, for instance, has implemented the National Strategy for Genomic Medicine, which facilitates research and development in this area. Additionally, collaboration between public health agencies and research institutions is encouraged to streamline the regulatory approval process for new therapies. Such supportive frameworks inspire increased investment in developing personalized medicine solutions, thus driving market expansion throughout the region. ### **Growing Awareness and Education Among Healthcare Professionals** The increasing awareness and education surrounding personalized medicine among healthcare professionals is another key driver for the South America Personalized Medicine Market. As healthcare providers become more knowledgeable about the benefits of personalized therapies, patient demand for tailored treatment solutions rises. Organizations such as the Latin American Society of Medical Oncology (LASMO) actively promote educational programs that inform oncologists and other specialists about the development and application of personalized medicine. This growing awareness translates into a more substantial push towards adopting innovative treatment options in clinical practice across South America, ultimately contributing to market growth. ## **South America Personalized Medicine Market Segment Insights** ### **Personalized Medicine Market Product Outlook Insights** The South America Personalized Medicine Market is set to experience robust growth driven by advancements in technology and an increasing focus on tailored healthcare solutions. Within the Product Outlook, a multitude of areas such as Personalized Medicine Diagnostics, Personalized Medicine Therapeutics, Personalized Medical Care, and Personalized Nutrition and Wellness are gaining traction. Personalized Medicine Diagnostics is crucial as it enables healthcare providers to identify the most effective treatments based on an individual's unique genetic makeup, leading to higher success rates in patient care. Personalized Medicine Therapeutics plays a pivotal role in targeting specific diseases with precision, making treatments more effective, and minimizing adverse reactions. The significance of Personalized Medical Care is reflected in its holistic approach to healthcare, emphasizing comprehensive patient management that aligns with individual health requirements. Additionally, Personalized Nutrition and Wellness nurtures a growing awareness regarding the importance of tailored nutritional strategies, which can significantly benefit health outcomes and chronic disease management. As these sectors continue to evolve, the South America Personalized Medicine Market stands to gain immense momentum, driven by regulatory support for innovative healthcare solutions and heightened public interest in personalized healthcare approaches. The region's investment in healthcare infrastructure and research provides a fertile ground for growth, making it essential for stakeholders to focus on these specific aspects in order to harness the full potential of personalized medicine. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Personalized Medicine Market Application Outlook Insights** The South America Personalized Medicine Market showcases a noteworthy segmentation within the Application Outlook, reflecting its diverse applications spanning Oncology, CNS, Immunology, Respiratory, and others. Oncology stands out as a significant area, responding to the rising prevalence of cancers across the region, driving advancements in targeted therapies. Similarly, the Central Nervous System (CNS) applications are gaining momentum, addressing disorders such as Alzheimer’s and multiple sclerosis, which are increasingly recognized in South America. Immunology remains another critical focus, as the growing incidence of autoimmune diseases necessitates tailored treatment approaches. The Respiratory segment attracts attention due to the heightened awareness surrounding chronic conditions like asthma and COPD, underscoring the need for precision in treatment options. Additionally, the 'Others' category encapsulates a variety of innovative treatments tailored to unique patient needs. Overall, the South America Personalized Medicine Market data is indicative of a robust ecosystem supported by advancements in technology and escalating demand for customized healthcare solutions. This market growth is further fueled by a proactive healthcare policy environment aimed at enhancing patient outcomes through personalized treatment methodologies. ### **Personalized Medicine Market End-User Outlook Insights** The South America Personalized Medicine Market exhibits a diverse End-User Outlook, with significant contributions from various sectors such as hospitals, diagnostic centers, research, and academic institutes. Hospitals serve as crucial players in the distribution of personalized medicine, providing tailored treatment options that cater to individual patient needs. This segment increasingly adopts advanced technologies and genetic testing to enhance patient care and treatment outcomes. Diagnostic centers are pivotal as well, facilitating early detection and personalized therapies, thereby driving the demand for precision medicine. Research and academic institutes play a vital role in the development and innovation of personalized medicine, underlining their importance in shaping the future of healthcare in the region. With ongoing investments in research and raising awareness about personalized treatment benefits, these institutions significantly contribute to advancements in personalized medicine initiatives. Other segments, though smaller, still represent an essential aspect of the market, signifying the diverse applications of personalized medicine across various fields. Overall, the growth and evolution of the South America Personalized Medicine Market rely heavily on these end-user segments, reflecting a broader trend towards individualized healthcare in the region. ## **South America Personalized Medicine Market Key Players and Competitive Insights** The South America Personalized Medicine Market is increasingly recognized for its potential to revolutionize healthcare by offering tailored treatments based on individual genetic profiles and health conditions. This market is characterized by rapid technological advancements in genomics, biotechnology, and pharmacogenomics, allowing healthcare providers to deliver more precise and effective therapies. The competitive landscape is shaped by both established pharmaceutical companies and innovative startups, all striving to capture market share by developing unique personalized medicine solutions. Factors such as the increasing prevalence of chronic diseases, rising demand for advanced therapeutic solutions, and supportive government initiatives to promote personalized healthcare strategies contribute to a dynamic market environment. The competition also hinges on strategic collaborations, partnerships, and investments aimed at advancing research and development capabilities. Laboratorio Farmaceutico Fagron stands out in the South America Personalized Medicine Market with a robust presence driven by its commitment to innovation and quality. The company specializes in developing personalized compounded medications, catering to the unique needs of healthcare professionals and patients. Its focus on creating tailored drug formulations positions Laboratorio Farmaceutico Fagron as a dual player in both the pharmaceutical industry and personalized medicine space. The company leverages its substantial expertise in compounding techniques to offer customized solutions that enhance patient care. Laboratorio Farmaceutico Fagron’s operations are bolstered by state-of-the-art facilities and a dedicated workforce that emphasizes compliance with regulatory standards. The company’s ongoing investment in research and development further reinforces its strengths, enabling it to adapt swiftly to changing market demands and emerging healthcare trends. Grupo Petersen operates strategically within the South America Personalized Medicine Market with a focus on expanding its product offerings and improving patient outcomes. The company provides an array of services that include genetic testing, molecular diagnostics, and personalized therapeutic solutions tailored to individual patient profiles. Grupo Petersen's strengths lie in its strong distribution networks, extensive relationships with healthcare providers, and commitment to quality assurance in all its products and services. The company has made significant strides in the region through strategic mergers and acquisitions, facilitating the integration of innovative technologies and broadening its market reach. These moves have allowed Grupo Petersen to enhance its capabilities in the personalized medicine arena, reinforcing its commitment to delivering high-quality, tailored health solutions to meet the diverse needs of the South American patient population. The combination of in-depth industry knowledge and a customer-centric approach has solidified Grupo Petersen’s position as a key player in this evolving market. ### **Key Companies in the South America Personalized Medicine Market Include** - Laboratorio Farmaceutico Fagron - Grupo Petersen - Dasa - Grupo Sabin - Progen Biotechnik - Biomarkers - Hermes Pardini - Fleury Group - **[Laboratorio Elea](https://elea.com/en/products/)** ## **South America Personalized Medicine Market Developments** The South America Personalized Medicine Market has witnessed significant developments recently, including a focus on expanding genetic testing and targeted therapies in countries like Brazil and Argentina. In June 2023, Dasa announced the acquisition of a local biotechnology firm, enhancing its capabilities in genomics and personalized healthcare solutions. Additionally, the growth of Laboratorio Farmaceutico Fagron has been notable, as the company reported an increase in its market valuation due to the adoption of innovative drug delivery systems tailored to individual patient needs. Grupo Sabin and Fleury Group have also made strides in advancing laboratory services, improving access to personalized diagnostics across the region. The market's expansion has been fueled by a growing emphasis on precision medicine as a cornerstone of healthcare policy in South America, with ministries in various countries advocating for the integration of personalized healthcare in public health agendas. In the last 2-3 years, there has been a notable increase in public and private investments in biotechnology research and development, driving advancements in personalized treatments and diagnostics across South America. ## **South America Personalized Medicine Market Segmentation Insights** ### **Personalized Medicine Market Product Outlook** - Personalized Medicine Diagnostics - Personalized Medicine Therapeutics - Personalized Medical Care - Personalized Nutrition and Wellness ### **Personalized Medicine Market Application Outlook** - Oncology - CNS - Immunology - Respiratory - Others ### **Personalized Medicine Market End-User Outlook** - Hospitals - Diagnostic Centers - Research Academic Institutes - Others ## Market Drivers ### Government Initiatives and Support Government initiatives aimed at promoting personalized medicine are playing a crucial role in shaping the market landscape in South America. Various countries in the region are implementing policies to support research and development in genomics and biotechnology. For instance, funding programs and tax incentives for companies engaged in personalized medicine research are becoming more prevalent. These initiatives not only foster innovation but also encourage collaboration between public and private sectors. As a result, the personalized medicine market is expected to benefit from increased investment, potentially reaching a valuation of $5 billion by 2030. ### Rising Demand for Tailored Therapies The increasing prevalence of chronic diseases in South America is driving the demand for tailored therapies within the personalized medicine market. As healthcare providers seek to improve patient outcomes, there is a noticeable shift towards treatments that consider individual genetic profiles. This trend is particularly evident in oncology, where personalized therapies have shown to enhance efficacy and reduce adverse effects. According to recent estimates, the personalized medicine market in South America is projected to grow at a CAGR of approximately 12% from 2025 to 2030. This growth is indicative of a broader recognition of the need for customized treatment plans that align with patients' unique biological characteristics. ### Advancements in Diagnostic Technologies Innovations in diagnostic technologies are significantly impacting the personalized medicine market in South America. Enhanced genomic sequencing techniques and biomarker identification methods are enabling healthcare professionals to make more informed decisions regarding treatment options. These advancements facilitate the early detection of diseases and the identification of specific patient subgroups that may benefit from targeted therapies. As a result, the market is witnessing a surge in the adoption of precision diagnostics, which is expected to account for nearly 30% of the overall personalized medicine market by 2030. This shift underscores the importance of accurate diagnostics in tailoring treatment strategies. ### Collaboration Between Academia and Industry The collaboration between academic institutions and the pharmaceutical industry is emerging as a key driver for the personalized medicine market in South America. Research partnerships are facilitating the translation of scientific discoveries into clinical applications, thereby accelerating the development of innovative therapies. These collaborations often focus on the identification of genetic markers and the development of targeted treatments. As a result, the personalized medicine market is expected to see a significant influx of novel therapies, with projections indicating that new product launches could increase by 25% over the next five years. This synergy between academia and industry is vital for advancing personalized medicine initiatives. ### Growing Awareness Among Healthcare Professionals There is a notable increase in awareness among healthcare professionals regarding the benefits of personalized medicine in South America. Medical practitioners are increasingly recognizing the potential of tailored treatments to improve patient outcomes and reduce healthcare costs. This growing awareness is leading to enhanced training programs and educational initiatives focused on genomics and personalized therapies. As healthcare providers become more knowledgeable about the advantages of personalized medicine, the market is likely to experience accelerated growth. It is estimated that by 2030, approximately 40% of healthcare professionals in the region will be actively engaged in personalized medicine practices. ## Future Outlook The [Personalized Medicine Market](https://www.marketresearchfuture.com/reports/personalized-medicine-market-2937) is projected to grow at a 5.9% CAGR from 2025 to 2035, driven by advancements in genomics, increased healthcare spending, and rising demand for tailored therapies. **New opportunities:** - Development of AI-driven diagnostic tools for personalized treatment plans. - Expansion of telemedicine platforms for remote patient monitoring and consultations. - Partnerships with biotech firms to enhance drug development pipelines. By 2035, the personalized medicine market will achieve substantial growth and innovation. ## Segment Insights ### By Product: Personalized Medicine Diagnostics (Largest) vs. Personalized Medicine Therapeutics (Fastest-Growing) In the South America personalized medicine market, Personalized Medicine Diagnostics holds the largest share, showcasing the critical role of diagnostic tools in tailored healthcare solutions. This segment benefits from increasing healthcare expenditures and heightened awareness among patients regarding personalized treatment options, leading to a more significant adoption rate in clinical settings. In contrast, Personalized Medicine Therapeutics has emerged as the fastest-growing segment, fueled by advancements in genetic research and the rising prevalence of chronic diseases requiring customized therapeutic approaches. The growth trends within this segment are driven by technological innovations, expanding access to genetic testing, and a surge in demand for individualized treatment plans. Additionally, collaborations between biotech firms and healthcare providers are boosting the development and availability of personalized therapeutics. The increasing focus on preventive healthcare further propels this growth, as patients seek more effective treatment pathways tailored to their unique genetic profiles. Personalized Medicine Diagnostics (Dominant) vs. Personalized Medicine Therapeutics (Emerging) Personalized Medicine Diagnostics is characterized by its essential role in identifying disease predispositions and guiding treatment choices. It includes advanced technologies such as genomic sequencing and biomarker discovery, positioning itself as a vital component in the healthcare landscape. In contrast, Personalized Medicine Therapeutics is emerging swiftly, focusing on tailoring treatment regimens based on individual genetic profiles and responses to various drugs. This segment is gaining traction due to the shift toward precision medicine, where the efficacy of drug therapies is maximized by aligning them with specific patient demographics and genetic markers. Both segments, while distinct, contribute significantly to transforming healthcare practices in South America. ### By Application: Oncology (Largest) vs. CNS (Fastest-Growing) In the Application segment, Oncology emerges as the largest contributor, reflecting a significant focus on cancer treatment solutions that leverage personalized medicine. Following closely are CNS and Immunology, demonstrating healthy market shares. Respiratory applications hold a small yet important role, while the 'Others' category includes niche therapies. This distribution highlights the variation in healthcare needs across different therapeutic areas, with Oncology taking a commanding lead in market presence. Growth trends indicate that the demand for personalized medicine in the CNS segment is accelerating, driven by advancements in genomics and targeted therapies. Innovations in drug development tailored for individual responses are expected to catapult this segment as the fastest-growing. Additionally, increasing investment in research and a greater emphasis on individualized healthcare are fueling expansion across all areas, pointing towards a robust future for personalized applications. Oncology (Dominant) vs. CNS (Emerging) Oncology continues to dominate the application landscape in personalized medicine, driven by extensive research and tailored treatment plans that enhance patient outcomes. This segment benefits from cutting-edge technologies that assess genetic profiles, allowing for bespoke therapies aimed at specific cancer types. In contrast, the CNS segment, while currently smaller, is regarded as an emerging force. Innovations such as biologics and targeted therapies are gaining traction, transforming treatment approaches for neurological disorders. With the rise in mental health awareness and the ongoing research in personalized approaches to CNS diseases, this segment is poised for significant growth, making it an area of interest for stakeholders in the personalized medicine landscape. ### By End-User: Hospitals (Largest) vs. Diagnostic Centers (Fastest-Growing) In the personalized medicine market, Hospitals hold the largest share among end-users, showcasing a significant demand for tailored treatment solutions, primarily due to their integration of advanced technologies and patient-centered care approaches. Conversely, Diagnostic Centers, while smaller in overall market share, are rapidly gaining traction as consumers increasingly seek precision diagnostics to inform personalized treatment plans. Both segments are crucial to the growth of personalized medicine in the region. Growth trends within these segments indicate an increasing focus on personalized approaches to healthcare, driven by advancements in genomics and biotechnology. Hospitals are investing in tailored therapies, while Diagnostic Centers are expanding capabilities in genetic testing and biomarker analysis. This dual trajectory indicates that as patient awareness rises, supported by technological innovation, the landscape of healthcare delivery is set for transformative changes across these end-user categories. Hospitals (Dominant) vs. Diagnostic Centers (Emerging) Hospitals stand as a dominant force in the personalized medicine market, characterized by their extensive resources and capacity to implement advanced treatment protocols. They are well-equipped to adopt personalized therapies, investing substantially in clinical trials and research that align with patients' genetic profiles. On the other hand, Diagnostic Centers are emerging as essential players, focusing on precision diagnostics that enable tailored therapies. With increasing investments in state-of-the-art diagnostic technologies, these centers are vital in facilitating targeted treatments and enhancing treatment efficacy. Together, these segments illustrate the evolving dynamics of healthcare delivery, where personalized approaches are becoming central to effective patient management. ## Regional Market Share Analysis ### Brazil : Strong Growth and Innovation Hub Brazil holds a dominant 30.0% market share in South America's personalized medicine sector, driven by increasing healthcare investments and a growing aging population. Key growth drivers include advancements in genomics and biotechnology, alongside supportive government initiatives aimed at enhancing healthcare access. Regulatory frameworks are evolving to facilitate faster approvals for personalized therapies, while infrastructure improvements in urban centers bolster distribution and accessibility. ### Mexico : Regulatory Reforms Boost Market Growth With a 10.0% market share, Mexico is rapidly emerging in the personalized medicine landscape. Growth is fueled by increasing investments in healthcare technology and a rising demand for tailored therapies. The government has implemented regulatory reforms to streamline the approval process for new treatments, enhancing market dynamics. Additionally, the expansion of healthcare infrastructure in urban areas supports the distribution of personalized medicine solutions. ### Argentina : Focus on Localized Healthcare Solutions Argentina accounts for an 8.0% share in the personalized medicine market, characterized by a focus on localized healthcare solutions. The growth is driven by increasing awareness of genetic testing and personalized therapies among healthcare providers and patients. Government initiatives are promoting research and development in biotechnology, while regulatory bodies are working to ensure the safety and efficacy of new treatments. The market is also supported by collaborations between local universities and pharmaceutical companies. ### Rest of South America : Varied Market Dynamics Across Regions The Rest of South America holds an 11.67% market share in personalized medicine, showcasing diverse opportunities across different countries. Growth is driven by varying healthcare needs and increasing investments in biotechnology. Regulatory environments differ significantly, with some countries adopting more progressive policies to encourage innovation. Infrastructure development is uneven, impacting market access and distribution channels for personalized therapies. ## Competitive Benchmarking The personalized medicine market in South America is characterized by a dynamic competitive landscape, driven by advancements in genomics, biotechnology, and a growing emphasis on tailored healthcare solutions. Key players such as Roche (CH), Thermo Fisher Scientific (US), and Novartis (CH) are at the forefront, leveraging their extensive research capabilities and innovative product pipelines. Roche (CH) focuses on integrating diagnostics with therapeutics, enhancing patient outcomes through precision medicine. Meanwhile, Thermo Fisher Scientific (US) emphasizes its role in providing comprehensive genomic solutions, which are crucial for personalized treatment strategies. Novartis (CH) is actively pursuing partnerships to expand its reach in the region, particularly in oncology, where personalized therapies are gaining traction. Collectively, these strategies foster a competitive environment that prioritizes innovation and collaboration.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The competitive structure of the market appears moderately fragmented, with several players vying for market share. However, the influence of major companies is substantial, as they set industry standards and drive technological advancements that smaller firms often follow. In October Roche (CH) announced a strategic partnership with a local biotech firm to develop personalized therapies for chronic diseases prevalent in South America. This collaboration is expected to enhance Roche's capabilities in tailoring treatments to the genetic profiles of local populations, thereby improving patient outcomes and expanding its market presence. The strategic importance of this move lies in its potential to address unmet medical needs in the region, aligning with global trends towards personalized healthcare. In September Novartis (CH) launched a new initiative aimed at increasing access to its personalized medicine portfolio in underserved areas of South America. This initiative includes educational programs for healthcare professionals and partnerships with local health authorities. The significance of this initiative is twofold: it not only broadens patient access to innovative therapies but also strengthens Novartis's reputation as a leader in responsible healthcare practices. In August Thermo Fisher Scientific (US) unveiled a new genomic sequencing platform tailored for the South American market, designed to facilitate rapid and cost-effective genetic testing. This development is crucial as it enhances the company's competitive edge by providing healthcare providers with the tools necessary for implementing personalized medicine strategies. The introduction of this platform indicates a shift towards more accessible genomic technologies, which could significantly impact patient care in the region. As of November current trends in the personalized medicine market include a pronounced focus on digitalization, sustainability, and the integration of artificial intelligence (AI) in research and development processes. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and the reliability of supply chains. This shift underscores the importance of adaptability and forward-thinking strategies in maintaining a competitive edge in the personalized medicine market. ## Recent News & Developments The South America Personalized Medicine Market has witnessed significant developments recently, including a focus on expanding genetic testing and targeted therapies in countries like Brazil and Argentina. In June 2023, Dasa announced the acquisition of a local biotechnology firm, enhancing its capabilities in genomics and personalized healthcare solutions. Additionally, the growth of Laboratorio Farmaceutico Fagron has been notable, as the company reported an increase in its market valuation due to the adoption of innovative drug delivery systems tailored to individual patient needs. Grupo Sabin and Fleury Group have also made strides in advancing laboratory services, improving access to personalized diagnostics across the region. The market's expansion has been fueled by a growing emphasis on precision medicine as a cornerstone of healthcare policy in South America, with ministries in various countries advocating for the integration of personalized healthcare in public health agendas. In the last 2-3 years, there has been a notable increase in public and private investments in biotechnology research and development, driving advancements in personalized treatments and diagnostics across South America. ## Report Scope | MARKET SIZE 2024 | 59.67(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 63.19(USD Billion) | | MARKET SIZE 2035 | 112.14(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.9% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Roche (CH), Thermo Fisher Scientific (US), Illumina (US), Novartis (CH), GSK (GB), Pfizer (US), AbbVie (US), Bristol-Myers Squibb (US), Amgen (US) | | Segments Covered | Product, Application, End-User | | Key Market Opportunities | Emergence of advanced genomic technologies enhances tailored therapies in the personalized medicine market. | | Key Market Dynamics | Rising demand for tailored therapies drives innovation and competition in the personalized medicine market. | | Countries Covered | Brazil, Mexico, Argentina, Rest of South America | ## Frequently Asked Questions **Q: What was the overall market valuation for personalized medicine in South America in 2024?** A: The overall market valuation for personalized medicine in South America was $59.67 Billion in 2024. **Q: What is the projected market valuation for personalized medicine in South America by 2035?** A: The projected market valuation for personalized medicine in South America is $112.14 Billion by 2035. **Q: What is the expected CAGR for the South America personalized medicine market during the forecast period 2025 - 2035?** A: The expected CAGR for the South America personalized medicine market during the forecast period 2025 - 2035 is 5.9%. **Q: Which companies are considered key players in the South America personalized medicine market?** A: Key players in the South America personalized medicine market include Roche, Thermo Fisher Scientific, Illumina, Novartis, GSK, Pfizer, AbbVie, Bristol-Myers Squibb, and Amgen. **Q: What was the valuation of personalized medicine diagnostics in 2024?** A: The valuation of personalized medicine diagnostics in 2024 was $10.0 Billion. **Q: What is the projected valuation for personalized medicine therapeutics by 2035?** A: The projected valuation for personalized medicine therapeutics is $45.0 Billion by 2035. **Q: How much is the personalized nutrition and wellness segment expected to grow by 2035?** A: The personalized nutrition and wellness segment is expected to grow to $24.14 Billion by 2035. **Q: What was the market size for oncology applications in 2024?** A: The market size for oncology applications in 2024 was $20.0 Billion. **Q: What is the projected market size for hospitals as end-users of personalized medicine by 2035?** A: The projected market size for hospitals as end-users of personalized medicine is $38.0 Billion by 2035. **Q: What was the valuation of the immunology application segment in 2024?** A: The valuation of the immunology application segment in 2024 was $12.0 Billion. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-america-personalized-medicine-market-45315*